BR112022015303A2 - Biomarcadores de esteato-hepatite não alcoólica (nash) e usos dos mesmos - Google Patents

Biomarcadores de esteato-hepatite não alcoólica (nash) e usos dos mesmos

Info

Publication number
BR112022015303A2
BR112022015303A2 BR112022015303A BR112022015303A BR112022015303A2 BR 112022015303 A2 BR112022015303 A2 BR 112022015303A2 BR 112022015303 A BR112022015303 A BR 112022015303A BR 112022015303 A BR112022015303 A BR 112022015303A BR 112022015303 A2 BR112022015303 A2 BR 112022015303A2
Authority
BR
Brazil
Prior art keywords
nash
alcoholic steatohepatitis
biomarkers
individual
hepatic
Prior art date
Application number
BR112022015303A
Other languages
English (en)
Inventor
Alexander Leigh
Ostroff Rachel
Field Stuart
Original Assignee
Somalogic Operating Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Somalogic Operating Co Inc filed Critical Somalogic Operating Co Inc
Publication of BR112022015303A2 publication Critical patent/BR112022015303A2/pt

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/08—Hepato-biliairy disorders other than hepatitis
    • G01N2800/085—Liver diseases, e.g. portal hypertension, fibrosis, cirrhosis, bilirubin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

BIOMARCADORES DE ESTEATO-HEPATITE NÃO ALCOÓLICA (NASH) E USOS DOS MESMOS. A presente invenção refere-se a métodos, composições e kits para determinar se um indivíduo tem uma condição hepática, incluindo esteatose hepática, inflamação hepática, balonismo hepatocelular e/ou fibrose hepática. Em várias modalidades, a condição hepática do indivíduo inclui esteato-hepatite não alcoólica (NASH).
BR112022015303A 2020-02-10 2021-02-09 Biomarcadores de esteato-hepatite não alcoólica (nash) e usos dos mesmos BR112022015303A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202062972418P 2020-02-10 2020-02-10
PCT/US2021/017217 WO2021163034A1 (en) 2020-02-10 2021-02-09 Nonalcoholic steatohepatitis (nash) biomarkers and uses thereof

Publications (1)

Publication Number Publication Date
BR112022015303A2 true BR112022015303A2 (pt) 2022-09-27

Family

ID=74858782

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022015303A BR112022015303A2 (pt) 2020-02-10 2021-02-09 Biomarcadores de esteato-hepatite não alcoólica (nash) e usos dos mesmos

Country Status (11)

Country Link
US (1) US20230071234A1 (pt)
EP (1) EP4103948A1 (pt)
JP (1) JP2023512701A (pt)
KR (1) KR20220140727A (pt)
CN (1) CN115066616A (pt)
AU (1) AU2021220787A1 (pt)
BR (1) BR112022015303A2 (pt)
CA (1) CA3166923A1 (pt)
IL (1) IL295064A (pt)
MX (1) MX2022009517A (pt)
WO (1) WO2021163034A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023238881A1 (ja) * 2022-06-07 2023-12-14 日東電工株式会社 非アルコール性脂肪性肝疾患（ｎａｆｌｄ）または非アルコール性脂肪肝炎（ｎａｓｈ）を診断するためのマーカー

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5660985A (en) 1990-06-11 1997-08-26 Nexstar Pharmaceuticals, Inc. High affinity nucleic acid ligands containing modified nucleotides
US6001577A (en) 1998-06-08 1999-12-14 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: photoselection of nucleic acid ligands and solution selex
US5580737A (en) 1990-06-11 1996-12-03 Nexstar Pharmaceuticals, Inc. High-affinity nucleic acid ligands that discriminate between theophylline and caffeine
US5763177A (en) 1990-06-11 1998-06-09 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: photoselection of nucleic acid ligands and solution selex
EP1695978A1 (en) 1990-06-11 2006-08-30 Gilead Sciences, Inc. Nucleic acid ligands
US5705337A (en) 1990-06-11 1998-01-06 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: chemi-SELEX
US6458539B1 (en) 1993-09-17 2002-10-01 Somalogic, Inc. Photoselection of nucleic acid ligands
US6242246B1 (en) 1997-12-15 2001-06-05 Somalogic, Inc. Nucleic acid ligand diagnostic Biochip
US7855054B2 (en) 2007-01-16 2010-12-21 Somalogic, Inc. Multiplexed analyses of test samples
US7947447B2 (en) 2007-01-16 2011-05-24 Somalogic, Inc. Method for generating aptamers with improved off-rates
US7824871B2 (en) * 2007-06-14 2010-11-02 George Mason Intellectual Properties Methods of diagnosing non-alcoholic steatohepatitis (NASH)
ES2533711T3 (es) 2007-07-17 2015-04-14 Somalogic, Inc. Aptámeros con uridinas 5-(N-naftil)-sustituidas
AU2011274422B2 (en) 2010-07-09 2016-02-11 Somalogic Operating Co., Inc. Lung cancer biomarkers and uses thereof
CA2809282C (en) 2010-09-27 2017-09-12 Somalogic, Inc. Mesothelioma biomarkers and uses thereof
BR122019026188B1 (pt) * 2013-03-15 2024-01-02 Somalogic Operating Co., Inc Métodos para determinar se um indivíduo com esteatose não alcoólica tem esteato-hepatite não alcoólica e para monitorar um indivíduo com esteatose não alcoólica para o desenvolvimento de nash
US20180155787A1 (en) * 2015-06-05 2018-06-07 Regulus Therapeutics Inc. Non-alcoholic fatty liver disease biomarkers
ES2955883T3 (es) * 2015-06-19 2023-12-07 Sera Prognostics Inc Pares de biomarcadores para la predicción del parto prematuro
US9725769B1 (en) * 2016-10-07 2017-08-08 Oncology Venture ApS Methods for predicting drug responsiveness in cancer patients

Also Published As

Publication number Publication date
EP4103948A1 (en) 2022-12-21
CN115066616A (zh) 2022-09-16
MX2022009517A (es) 2022-09-02
IL295064A (en) 2022-09-01
US20230071234A1 (en) 2023-03-09
AU2021220787A1 (en) 2022-09-01
KR20220140727A (ko) 2022-10-18
WO2021163034A1 (en) 2021-08-19
JP2023512701A (ja) 2023-03-28
CA3166923A1 (en) 2021-08-19

Similar Documents

Publication Publication Date Title
BR112018014842A2 (pt) biomarcadores de doenças hepática gordurosa não alcoólica (nafld) e esteato-hepatite não alcoólica (nash) e utilização dos mesmos
PH12017501384A1 (en) Pharmaceutical compositions for combination therapy
BRPI0607556A2 (pt) sistemas e métodos que combinam serviços de subscrição, programas de prêmios, e loteria
PH12017501841A1 (en) Method for discriminating symptom of hepatic disease
BR112013000110A2 (pt) composições de limpeza e processo de limpeza
BR112014004444A2 (pt) composições e métodos que compreendem uma variante de enzima lipolítica
WO2006023966A3 (en) Assessment of cardiovascular risk
BR112014014410A2 (pt) composições e métodos que compreendem uma variante de enzima lipolítica
BRPI0906104B8 (pt) derivado de ácido peptonucleico, composição farmacêutica contendo uma quantidade terapeuticamente eficaz do derivado de ácido peptonucleico, método de utilização do derivado de ácido peptonucleico e composto
BR112022015303A2 (pt) Biomarcadores de esteato-hepatite não alcoólica (nash) e usos dos mesmos
BR112015018434A2 (pt) método, e, conjunto para medir uma vitamina d
BRPI0518414A2 (pt) dispositivo para troca de calor para gases com teor de Ácido
BRPI0701267A (pt) verniz
BR112012012476A2 (pt) "composições nutritivas incluindo um componente de alta proteína e nucleotídeos exôgenos"
WO2017040407A8 (en) Compositions and methods for the reduction or prevention of non-alcoholic steatohepatitis (nash)
BR112018002184A2 (pt) composição adesiva aquosa à base de resina de epoxia com aderência melhorada e estabilidade de armazenamento
BR112015015371A2 (pt) realçador de aparência para composições de borracha com antidegradantes
NZ586423A (en) Liver function-protecting agent comprising a phospholipid
WO2019126097A8 (en) High mobility group box-1 (hmgb1) irna compositions and methods of use thereof
WO2006096735A8 (en) Enhancing a luminescent signal
WO2019039817A3 (ko) 간질환 예측 또는 진단용 조성물 및 이를 이용한 간질환 예측 또는 진단 방법
BR112015011515A2 (pt) Composições farmacêuticas de inibidores de cetp
BR112022007252A2 (pt) Método de tratamento de uma doença hepática e composição
BR112023018714A2 (pt) Uso de um inibidor de line-1 para tratar ou prevenir ataxia-telangiectasia, degeneração macular relacionada à idade, lúpus eritematoso sistêmico, doença autoimune associada a ifn, anemia de fanconi, fibrose pulmonar idiopática ou doença cardiovascular e kit que compreende um inibidor de line-1
BRPI0601779A (pt) composições de toner com polìmeros contendo amino como aditivos de superfìcie